Vounatsos Out as Biogen Appears to Concede Defeat Over Aduhelm

Bruised and battered by its failings with controversial Alzheimer’s drug Aduhelm, Biogen is looking to right the ship with a new helmsman. The company is on the hunt for a new chief executive officer.